A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
NCT06990880
This study is recruiting at 6 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Neoplasms, Prostate
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- GlaxoSmithKline
- Last updated on ClinicalTrials.gov
- October 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- GSK Investigational Site · Phoenix, AZ
Colorado · 1
- GSK Investigational Site · Denver, CO
Connecticut · 1
- GSK Investigational Site · New Haven, CT
Minnesota · 1
- GSK Investigational Site · Rochester, MN
New Jersey · 1
- GSK Investigational Site · East Brunswick, NJ
Tennessee · 1
- GSK Investigational Site · Nashville, TN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.